Cinalukast
Cinalukast structure
|
Common Name | Cinalukast | ||
|---|---|---|---|---|
| CAS Number | 128312-51-6 | Molecular Weight | 412.54500 | |
| Density | 1.258g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C23H28N2O3S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death.
J. Physiol. Pharmacol. 60(3) , 135-43, (2009) Eryptosis, the suicidal death of erythrocytes, is characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine exposure at the erythrocyte surface. Eryptosis is triggered by increase in cytosolic Ca(2+) concentration upon energy deplet... |
|
|
Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast.
J. Allergy Clin. Immunol. 99(2) , 210-5, (1997) The degree and duration of protection against exercise-induced bronchoconstriction afforded by three doses of a specific leukotriene D4 receptor antagonist, cinalukast, were assessed after an initial dosing and after 1 week of therapy.A placebo-controlled cro... |
|
|
Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma.
Biochem. Pharmacol. 44(7) , 1411-5, (1992) We have identified and characterized two different subclasses of binding site for the novel peptido-leukotriene (LT) antagonist, [3H]ICI 198,615, in membranes from human lung parenchyma using a receptor-ligand assay. This novel compound is representative of a... |
|
|
Pharmacologic actions of Ro 24-5913, a novel antagonist of leukotriene D4.
J. Pharmacol. Exp. Ther. 259(2) , 751-8, (1991) Ro 24-5913, (E)-4-[3-[2-(4-cyclobutyl-2- thiazolyl)ethenyl]phenylamino]-2,2-diethyl-4-oxobutanoic acid, has been identified as a chemically unique, potent and selective LTD4 antagonist. In vitro, Ro 24-5913 competes with [3H]LTD4 for its binding site on guine... |
|
|
Temperature sensitivity of suicidal erythrocyte death.
Eur. J. Clin. Invest. 40(6) , 534-40, (2010) Fever and hyperthermia are frequently associated with anaemia. Under most clinical conditions, they are considered to be two mutually independent clinical consequences of a common cause. The present study explored the possibility that anaemia results from tem... |
|
|
Synergism exhibited by LTD4 and PAF receptor antagonists in decreasing antigen-induced airway microvascular leakage.
Adv. Prostaglandin. Thromboxane. Leukot. Res. 23 , 271-3, (1995)
|
|
|
Structure optimization of a leukotriene D4 antagonist by combinatorial chemistry in solution.
Bioorg. Med. Chem. 5(3) , 493-6, (1997) Structure optimization of the leukotriene D4 antagonist Ro24-5913 was attempted by combinatorial chemistry. Three segments in its N-succinyl-3-(2-thiazolylethenyl)anilide skeleton, designated as A, B, and C coincided with the thiazolyl, aniline, and N-acyl mo... |
|
|
Studies of the combination of Ro 24-5913, a peptidoleukotriene antagonist, and Ro 24-4736, a PAF antagonist, in guinea pig and rat models of lung inflammation.
Ann. N. Y. Acad. Sci. 744 , 274-88, (1994)
|
|
|
Complexation study of cinalukast and montelukast with cyclodextrines.
J. Pharm. Biomed. Anal. 43(3) , 1025-32, (2007) A fluorimetric study on the spectral characteristics of two antileukotrienes, cinalukast and montelukast, has been performed. Ionization constants of both of them have been photometrically calculated. Cinalukast pK(a) in ethanol:water 50:50 (v/v) medium resul... |
|
|
Degradation profile and reversed-phase LC method development of the antiinflammatory drug, Ro 24-5913.
J. Pharm. Biomed. Anal. 11(10) , 1037-43, (1993)
|